Xiang Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiang Deng has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Bing Wang
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People’s Republic of China
3 shared publications- Yuanyin Teng
Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, 310003, People’s Republic of China
3 shared publications - Zhongsong Zhang
The Second Affiliated Hospital of Chengdu Medical College, Nuclear Industry 416 Hospital, Chengdu, China
3 shared publications - Hao Sun
Wolfson Institute for Biomedical Research, UCL Division of Medicine, University College London, London, UK
2 shared publications - Long Chen
The Second Affiliated Hospital of Chengdu Medical College, Nuclear Industry 416 Hospital, Chengdu, Sichuan, 610000, People’s Republic of China
2 shared publications Zhongsong Zhang
School of Clinical Medicine, Chengdu Medical College, Chengdu, Sichuan, 610500, People’s Republic of China
2 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-60
Nanomedicine-Enhanced CAR-Engineered Immunotherapy for Lung Cancer: Focusing on Multimodal Strategies and Precision Therapy
Lung cancer remains a major therapeutic challenge because of its molecular and antigenic heterogeneity, rapid evolution, treatment resistance, and immunosuppressive tumor microenvironment (TME). Although chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment of hematological malignancies, its efficacy in lung cancer remains constrained by antigen heterogeneity, poor tumor trafficking and infiltration, T-cell dysfunction, suppressive stromal and myeloid compartments, manufacturing complexity, and pulmonary on-target off-tumor toxicity. Nanomedicine offers a versatile platform to address these barriers by improving CAR-T manufacturing and functional fitness, enabling targeted delivery of nucleic acids and immunomodulators, remodeling the TME, enhancing local accumulation and controlled activation, and supporting transient in situ generation of CAR-engineered immune cells. This review integrates these advances within a Route–Antigen–Microenvironment–Programming (RAMP) framework and emphasizes the mechanistic interdependence among delivery route, target selection, local tumor ecology, and CAR generation and control. We examine the antigen landscapes of non-small-cell and small-cell lung cancer and propose a quantitative framework for antigen selection that incorporates antigen density, spatial and temporal heterogeneity, normal-tissue safety, and engineering compensability. We further discuss nanotechnology-assisted manufacturing, cell-surface nanobackpacks, tumor preconditioning, local biomaterial reservoirs, in vivo CAR programming, pulmonary delivery, multimodal therapy, and theranostic monitoring. Most nano-enabled approaches are still supported primarily by preclinical studies or evidence from non-lung-cancer settings, underscoring the need for standardized assessment of biodistribution, reproducibility, immunogenicity, pulmonary safety, and long-term material fate. Integrating quantitative antigen profiling with biodegradable and controllable materials and lung-relevant translational models may help advance CAR-engineered immunotherapy toward a spatially controlled, dynamically monitored, and personalized therapeutic platform for lung cancer.
- 1 November 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-60
Open AccessNanomedicine-Enhanced CAR-Engineered Immunotherapy for Lung Cancer: Focusing on Multimodal Strategies and Precision Therapy
Lung cancer remains a major therapeutic challenge because of its molecular and antigenic heterogeneity, rapid evolution, treatment resistance, and immunosuppressive tumor microenvironment (TME). Although chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment of hematological malignancies, its efficacy in lung cancer remains constrained by antigen heterogeneity, poor tumor trafficking and infiltration, T-cell dysfunction, suppressive stromal and myeloid compartments, manufacturing complexity, and pulmonary on-target off-tumor toxicity. Nanomedicine offers a versatile platform to address these barriers by improving CAR-T manufacturing and functional fitness, enabling targeted delivery of nucleic acids and immunomodulators, remodeling the TME, enhancing local accumulation and controlled activation, and supporting transient in situ generation of CAR-engineered immune cells. This review integrates these advances within a Route–Antigen–Microenvironment–Programming (RAMP) framework and emphasizes the mechanistic interdependence among delivery route, target selection, local tumor ecology, and CAR generation and control. We examine the antigen landscapes of non-small-cell and small-cell lung cancer and propose a quantitative framework for antigen selection that incorporates antigen density, spatial and temporal heterogeneity, normal-tissue safety, and engineering compensability. We further discuss nanotechnology-assisted manufacturing, cell-surface nanobackpacks, tumor preconditioning, local biomaterial reservoirs, in vivo CAR programming, pulmonary delivery, multimodal therapy, and theranostic monitoring. Most nano-enabled approaches are still supported primarily by preclinical studies or evidence from non-lung-cancer settings, underscoring the need for standardized assessment of biodistribution, reproducibility, immunogenicity, pulmonary safety, and long-term material fate. Integrating quantitative antigen profiling with biodegradable and controllable materials and lung-relevant translational models may help advance CAR-engineered immunotherapy toward a spatially controlled, dynamically monitored, and personalized therapeutic platform for lung cancer.
- Open Access
- 1 September 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-46
Nanomedicine-Empowered CAR-T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy
Multiple myeloma (MM) remains a difficult-to-cure hematologic malignancy. Although B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy has substantially deepened clinical responses in patients with relapsed/refractory MM, its broader clinical application remains constrained by post-treatment relapse, insufficient response durability, prolonged manufacturing timelines, and limited accessibility. Increasing evidence indicates that relapse after CAR-T therapy in MM arises not from a single mechanism but from the convergence of tumor antigen remodeling, CAR-T cell exhaustion, impaired metabolic fitness, and bone marrow microenvironment–mediated immunosuppression. Nanomedicine provides modular engineering strategies to address these interconnected barriers to therapeutic efficacy. For example, lipid nanoparticles, polymeric carriers, biomimetic nanoplatforms, and targeted delivery systems may optimize ex vivo CAR-T manufacturing, enable in vivo CAR-T cell generation, regulate BCMA antigen density, remodel the bone marrow niche, and facilitate dynamic monitoring of relapse risk. This review systematically examines the major biological mechanisms underlying relapse after CAR-T therapy in MM, with particular emphasis on both the therapeutic potential of nanotechnology and the translational challenges associated with CAR-T manufacturing optimization, in vivo immune programming, bone marrow microenvironment remodeling, and relapse control in the post-BCMA era. By integrating advances in tumor immunology, materials science, and hematologic oncology, this review proposes a conceptual framework and future research priorities for developing faster, more controllable, durable, and accessible CAR-T therapeutic strategies for MM.
- 1 September 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-46
Open AccessNanomedicine-Empowered CAR-T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy
Multiple myeloma (MM) remains a difficult-to-cure hematologic malignancy. Although B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy has substantially deepened clinical responses in patients with relapsed/refractory MM, its broader clinical application remains constrained by post-treatment relapse, insufficient response durability, prolonged manufacturing timelines, and limited accessibility. Increasing evidence indicates that relapse after CAR-T therapy in MM arises not from a single mechanism but from the convergence of tumor antigen remodeling, CAR-T cell exhaustion, impaired metabolic fitness, and bone marrow microenvironment–mediated immunosuppression. Nanomedicine provides modular engineering strategies to address these interconnected barriers to therapeutic efficacy. For example, lipid nanoparticles, polymeric carriers, biomimetic nanoplatforms, and targeted delivery systems may optimize ex vivo CAR-T manufacturing, enable in vivo CAR-T cell generation, regulate BCMA antigen density, remodel the bone marrow niche, and facilitate dynamic monitoring of relapse risk. This review systematically examines the major biological mechanisms underlying relapse after CAR-T therapy in MM, with particular emphasis on both the therapeutic potential of nanotechnology and the translational challenges associated with CAR-T manufacturing optimization, in vivo immune programming, bone marrow microenvironment remodeling, and relapse control in the post-BCMA era. By integrating advances in tumor immunology, materials science, and hematologic oncology, this review proposes a conceptual framework and future research priorities for developing faster, more controllable, durable, and accessible CAR-T therapeutic strategies for MM.
- Open Access
- 1 February 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-2
Comment on “Association of the Cumulative Inflammatory Index and Long-Term Mortality in Stroke-Associated Pneumonia” [Letter]
Letter for the article Association of the Cumulative Inflammatory Index and Long-Term Mortality in Stroke-Associated Pneumonia
- 1 February 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-2
Open AccessComment on “Association of the Cumulative Inflammatory Index and Long-Term Mortality in Stroke-Associated Pneumonia” [Letter]
Letter for the article Association of the Cumulative Inflammatory Index and Long-Term Mortality in Stroke-Associated Pneumonia
- Open Access
- 1 February 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-2
Comment on “Multi-Omics Association Analysis of Mitochondrial Genes in Hypertrophic Scars: Application of Mendelian Randomization” [Letter]
We read with interest the multi-omics Mendelian randomization (MR) analysis of mitochondrial genes and hypertrophic scars (HS) by Gong et al, which identifies HTATIP2 and PDK1 as putative causal genes. 1 The study is ambitious and innovative, yet several methodological and interpretative issues may temper the strength of the causal claims. First, all molecular instruments are derived from blood mQTL/eQTL/pQTL datasets, whereas HS is primarily a fibroblast-and dermis-dominated phenotype. Large consortia such as GTEx have shown that eQTL effects are frequently tissue-and even cell-type-specific, with many regulatory variants active in only a subset of tissues. 2 Multi-omics QTL resources likewise emphasize strong tissue/cell specificity. 3 The authors should more clearly acknowledge that their instruments may capture systemic immune or hematologic pathways rather than skin-or fibroblast-specific regulation, and ideally explore whether key signals replicate in skin/fibroblast QTL datasets. Second, the MR analyses use cis-SNPs pruned at r 2 =0.3 and then apply standard IVW/Egger models that assume independent instruments. Correlated variants can inflate precision, distort Cochran's Q, and compromise pleiotropy tests. Recent MR methods explicitly account for LD and complex correlated pleiotropy (eg, MR-Corr2, MR-CUE) and are recommended in exactly this setting. 4 Re-analysis with LD-aware MR would make the causal estimates more reliable. Third, while extensive sensitivity analyses are presented, residual horizontal pleiotropy is a major concern for mitochondrial genes that influence broad metabolic and inflammatory pathways. Contemporary guidance stresses that Egger, weighted median/mode and MR-PRESSO have limited power when instrument numbers are small or highly correlated, and that MR results should be interpreted as supportive rather than definitive evidence. 5 Fourth, the logic of multi-omics integration deserves greater caution. Colocalization identifies robust H4 support only for selected mQTL and eQTL signals, and no pQTL-HS colocalization is detected, yet HTATIP2 and PDK1 are promoted as tier-1 genes with convergent evidence. Current best practice recommends that MR findings be combined with consistent colocalization at each layer to reduce the risk that methylation, expression and protein signals arise from distinct causal variants in LD. 6 Recent methodological work on multi-omics MR also highlights the value of formal combination tests and mediation-oriented frameworks rather than heuristic tiering. 7 Finally, the biological interpretation of HTATIP2 and PDK1 could be further nuanced. Both genes are deeply embedded in generic angiogenic, apoptotic and metabolic networks, and prior studies suggest context-dependent, sometimes opposing roles across tissues and disease states. 8 Without integrating scar-specific cell states (myofibroblast activation, mechanotransduction, immune infiltration) and considering alternative pathways by which these genes may influence HS risk, the conclusion that they are ready therapeutic targets may be premature. Overall, this study identified 21 mitochondrial genes with therapeutic potential, which may enhance our understanding of the pathophysiology of HS. Meanwhile, addressing these issues, particularly the tissue specificity of the
- 1 February 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-2
Open AccessComment on “Multi-Omics Association Analysis of Mitochondrial Genes in Hypertrophic Scars: Application of Mendelian Randomization” [Letter]
We read with interest the multi-omics Mendelian randomization (MR) analysis of mitochondrial genes and hypertrophic scars (HS) by Gong et al, which identifies HTATIP2 and PDK1 as putative causal genes. 1 The study is ambitious and innovative, yet several methodological and interpretative issues may temper the strength of the causal claims. First, all molecular instruments are derived from blood mQTL/eQTL/pQTL datasets, whereas HS is primarily a fibroblast-and dermis-dominated phenotype. Large consortia such as GTEx have shown that eQTL effects are frequently tissue-and even cell-type-specific, with many regulatory variants active in only a subset of tissues. 2 Multi-omics QTL resources likewise emphasize strong tissue/cell specificity. 3 The authors should more clearly acknowledge that their instruments may capture systemic immune or hematologic pathways rather than skin-or fibroblast-specific regulation, and ideally explore whether key signals replicate in skin/fibroblast QTL datasets. Second, the MR analyses use cis-SNPs pruned at r 2 =0.3 and then apply standard IVW/Egger models that assume independent instruments. Correlated variants can inflate precision, distort Cochran's Q, and compromise pleiotropy tests. Recent MR methods explicitly account for LD and complex correlated pleiotropy (eg, MR-Corr2, MR-CUE) and are recommended in exactly this setting. 4 Re-analysis with LD-aware MR would make the causal estimates more reliable. Third, while extensive sensitivity analyses are presented, residual horizontal pleiotropy is a major concern for mitochondrial genes that influence broad metabolic and inflammatory pathways. Contemporary guidance stresses that Egger, weighted median/mode and MR-PRESSO have limited power when instrument numbers are small or highly correlated, and that MR results should be interpreted as supportive rather than definitive evidence. 5 Fourth, the logic of multi-omics integration deserves greater caution. Colocalization identifies robust H4 support only for selected mQTL and eQTL signals, and no pQTL-HS colocalization is detected, yet HTATIP2 and PDK1 are promoted as tier-1 genes with convergent evidence. Current best practice recommends that MR findings be combined with consistent colocalization at each layer to reduce the risk that methylation, expression and protein signals arise from distinct causal variants in LD. 6 Recent methodological work on multi-omics MR also highlights the value of formal combination tests and mediation-oriented frameworks rather than heuristic tiering. 7 Finally, the biological interpretation of HTATIP2 and PDK1 could be further nuanced. Both genes are deeply embedded in generic angiogenic, apoptotic and metabolic networks, and prior studies suggest context-dependent, sometimes opposing roles across tissues and disease states. 8 Without integrating scar-specific cell states (myofibroblast activation, mechanotransduction, immune infiltration) and considering alternative pathways by which these genes may influence HS risk, the conclusion that they are ready therapeutic targets may be premature. Overall, this study identified 21 mitochondrial genes with therapeutic potential, which may enhance our understanding of the pathophysiology of HS. Meanwhile, addressing these issues, particularly the tissue specificity of the
- Open Access
- 1 January 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-26
Novel Dual Strategy Based on EPR/AT for Optimizing Therapeutic Effect by Improving Drug Delivery System Physicochemical Properties and Regulating TME
The clinical advancement of cancer nanomedicine is significantly hindered by its limited accumulation in tumors, a key factor behind the frequent failure of nanodrugs in clinical trials. The effectiveness of these nanodrugs is closely tied to their route of administration, whether oral, transdermal, intravenous, or intracerebral, as each path presents unique physiological barriers that impede bioavailability and precise tumor targeting. Among the major causes of poor accumulation are rapid clearance by the mononuclear phagocyte system, opsonization accompanied by protein corona formation, renal filtration, and the abnormal, heterogeneous nature of tumor vasculature that restricts passive targeting via the enhanced permeability and retention (EPR) effect. In response, active targeting (AT) strategies have been widely explored, including surface modification with ligands, antibodies, or aptamers designed to bind specifically to overexpressed receptors on cancer cells or blood vessels. Despite these efforts, challenges such as the dense extracellular matrix, elevated interstitial fluid pressure, and the notable inconsistency of the EPR effect between animal models and human patients continue to limit therapeutic penetration. This review offers a systematic examination of nanodrug delivery pathways and the reasons behind their inadequate accumulation, highlighting the potential of both active targeting and combined passive-active strategies to enhance tumor-specific delivery. Overcoming these biological barriers through refined nano-design is crucial for developing the next generation of nanomedicines with improved tumor accumulation and treatment outcomes.
- 1 January 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-26
Open AccessNovel Dual Strategy Based on EPR/AT for Optimizing Therapeutic Effect by Improving Drug Delivery System Physicochemical Properties and Regulating TME
The clinical advancement of cancer nanomedicine is significantly hindered by its limited accumulation in tumors, a key factor behind the frequent failure of nanodrugs in clinical trials. The effectiveness of these nanodrugs is closely tied to their route of administration, whether oral, transdermal, intravenous, or intracerebral, as each path presents unique physiological barriers that impede bioavailability and precise tumor targeting. Among the major causes of poor accumulation are rapid clearance by the mononuclear phagocyte system, opsonization accompanied by protein corona formation, renal filtration, and the abnormal, heterogeneous nature of tumor vasculature that restricts passive targeting via the enhanced permeability and retention (EPR) effect. In response, active targeting (AT) strategies have been widely explored, including surface modification with ligands, antibodies, or aptamers designed to bind specifically to overexpressed receptors on cancer cells or blood vessels. Despite these efforts, challenges such as the dense extracellular matrix, elevated interstitial fluid pressure, and the notable inconsistency of the EPR effect between animal models and human patients continue to limit therapeutic penetration. This review offers a systematic examination of nanodrug delivery pathways and the reasons behind their inadequate accumulation, highlighting the potential of both active targeting and combined passive-active strategies to enhance tumor-specific delivery. Overcoming these biological barriers through refined nano-design is crucial for developing the next generation of nanomedicines with improved tumor accumulation and treatment outcomes.